Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Zoryve is also available in a 0.3% cream formulation for the treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. References: ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Although typical, plaque psoriasis is a frequently misunderstood disease. Many people think it is a skin condition, but it is an autoimmune disease that starts as inflammation inside the body.

People in the study had mild to severe plaque psoriasis, and the plaques covered 3% to 20% of their body surface area (BSA). Vtama cream or the placebo cream was applied once a day to plaque lesions.

Source Reference: Gooderham MJ, et al "Roflumilast foam, 0.3%, for psoriasis of the scalp and body: The ARRECTOR phase 3 randomized clinical trial" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol ...

Darier’s disease is a skin disorder that causes wart-like marks on the body that can flare up like psoriasis. You may be able to see the Auspitz sign on your skin, as people with the disease can ...

Apart from her plaque psoriasis advocacy work, Anthony has kept her eyes on the runway and spoke with WWD about some of her favorite trends, including the resurgence of vintage finds and pre-worn ...

Plaque psoriasis remission occurs when the skin clears and noticeable symptoms—such as scaling, redness, or itching—disappear. 2 Without a universally accepted definition of remission, its ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed. At week 8 ...